The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.50
Bid: 27.00
Ask: 28.00
Change: -0.50 (-1.79%)
Spread: 1.00 (3.704%)
Open: 28.00
High: 29.00
Low: 27.50
Prev. Close: 28.00
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jul 2020 07:00

RNS Number : 1837S
Renalytix AI PLC
07 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Renalytix AI Plc

213800NTOH3FK3WER551

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

 

Legal & General Assurance Society (LGAS)

 

Legal & General Assurance

(Pensions Management) Limited (PMC)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

 

02nd July 2020

 

6. Date on which issuer notified (DD/MM/YYYY):

 

06th July 2020

 

 

7. Total positions of person(s) subject to the notification obligation

 

 

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 3%

-

Below 3%

59,416,134

Position of previous notification (if

applicable)

3.11%

-

3.11%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYWL4Y04 (L&G)

Below 3%

-

Below 3%

-

SUBTOTAL 8. A

Below 3%

Below 3%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Group (Direct)

Below 3%

Below 3%

 

Legal & General Assurance Society (Direct)

 

Below 3%

 

Below 3%

 

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Group (Direct)

Below 3%

Below 3%

Legal & General Assurance (Pensions Management) Limited

(Direct)

Below 3%

Below 3%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General (Unit Trust Managers) Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Go ETF Solutions

Below 5%

Below 5%

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

 

 

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 59,416,134

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

06/07/2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFZGGNRVNGGZM
Date   Source Headline
25th Jun 20207:00 amRNSPublic filing re. Nasdaq dual-listing and offering
12th Jun 20207:00 amRNSKidneyIntelX™ receives New York State approval
10th Jun 20208:00 amRNSConfirmation of reduction of capital
10th Jun 20207:00 amRNSPositive results of clinical validation study
20th May 202011:06 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
20th May 20207:00 amRNSJV for COVID-19 antibody test scaled production
18th May 20207:00 amRNSProposed dual-listing on Nasdaq
15th May 20201:02 pmRNSResult of General Meeting
5th May 202010:55 amRNSRemoval of US Securities Law Restrictions
28th Apr 20207:00 amRNSUpdate re. potential demerger of FractalDx
27th Apr 20207:00 amRNSUtah Lab Facility Achieves ISO 13485 Certification
20th Apr 20207:00 amRNSKidneyIntelX used in Mount Sinai COVID-19 study
15th Apr 20207:00 amRNSProvider network agreement for KidneyIntelX™
1st Apr 20207:00 amRNSMedicare provider number
27th Mar 202010:32 amRNSHolding(s) in Company
27th Mar 20207:00 amRNSPresentation of KidneyIntelX Health Economics Data
24th Mar 20207:00 amRNSPodium Presentation and Publication for Data
3rd Mar 20207:00 amRNSHalf-year Report
26th Feb 20207:00 amRNSNotice of Results
25th Feb 20207:00 amRNSConference attendance
8th Jan 20207:00 amRNSNew commercial testing facility opens in Utah
3rd Jan 20207:00 amRNSCMS Pricing Determination becomes effective
3rd Dec 20197:00 amRNSMedicare sets US national price for KidneyIntelX
21st Nov 20197:00 amRNSGrant of Options
19th Nov 20197:00 amRNSRenalytixAI attending City Event for Kidney Health
17th Oct 20197:00 amRNSPartnership with CDPHP on KidneyIntelX
14th Oct 20197:00 amRNSBoard appointment
1st Oct 20197:00 amRNSUS CPT® reimbursement code effective
30th Sep 20194:37 pmRNSResult of AGM
30th Sep 20198:00 amRNSUpdate on non-executive director appointment
30th Sep 20197:00 amRNSPreliminary Medicare Pricing Determination
6th Sep 20194:00 pmRNSPosting of Annual Report & Accounts &Notice of AGM
3rd Sep 20197:00 amRNSFinal Results
20th Aug 20197:00 amRNSNotice of Results
6th Aug 20197:00 amRNSExpansion of Chronic Kidney Disease Advisory Board
31st Jul 20194:30 pmRNSTotal Voting Rights
29th Jul 20197:00 amRNSThomas McLain Appointed as President and CCO
23rd Jul 20196:23 pmRNSResult of Placing & Total Voting Rights
23rd Jul 20197:01 amRNSProposed Placing to raise £12.0m (c.US$15.0m)
12th Jul 20197:00 amRNSUS Exec Order on Advancing American Kidney Health
9th Jul 20197:00 amRNSPositive Interim Results for Validation Study
8th Jul 20197:00 amRNSFractalDx Positive Results Published in JASN
1st Jul 20197:00 amRNSUS CPT® Code Granted for KidneyIntelX(TM)
7th Jun 20197:00 amRNSPositive results from FractalDx study published
4th Jun 20197:00 amRNSKidneyIntelX commercial scale production milestone
28th May 20197:00 amRNSCLIA Certificate Number issued for Renalytix Lab
21st May 20197:00 amRNSExpansion of FractalDx core investigator group
7th May 20197:00 amRNSUniversity Medical Center Groningen collaboration
2nd May 20192:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.